Please find attached herewith the Transcript of Post Result Conference Call held on 4th August, 2026.

Date: 10th August, 2026 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 533573 NSE Symbol: APLLTD Dear Sir/Madam, Sub: Transcript of Post Results Conference Call held on 4th August, 2026 Ref: Our Intimation dated 27th July, 2026 With reference to the captioned matter, please find enclosed herewith the transcript of the Conference Call held on 4th August, 2026. We request you to kindly take the same on record. Thanking you, Yours faithfully, For Alembic Pharmaceuticals Limited Manisha Saraf Company Secretary Encl.: A/a. ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229 Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123 “Alembic Pharmaceuticals Limited Q1 FY27 Earnings Conference Call” August 04, 2026 MANAGEMENT: MR. PRANAV AMIN – MANAGING DIRECTOR– ALEMBIC PHARMACEUTICALS LIMITED MR. G. KRISHNAN – CHIEF FINANCIAL OFFICER – ALEMBIC PHARMACEUTICALS LIMITED MS. ISHA LAMBA – HEAD, INVESTOR RELATIONS AND CORPORATE DEVELOPMENT – ALEMBIC PHARMACEUTICALS LIMITED Page 1 of 15 Alembic Pharmaceuticals Limited August 04, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Q1 FY27 Earnings Conference Call of Alembic Pharmaceuticals Limited. As a reminder, this conference call is only for analysts and institutional investors. All participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star and then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Isha Lamba, Head, Investor Relations and Corporate Development. Thank you, and over to you, ma'am. Isha Lamba: Thank you. Good evening, everyone. On behalf of the management of Alembic Pharmaceuticals, I welcome you to this earnings conference call for the quarter ended 30th June 2026. Present here with me are Mr. Pranav Amin, Managing Director and Mr. G. Krishnan, CFO. A few other members of the management have also joined the call. I now hand the conference over to Mr. Pranav Amin. Thank you, and over to you, sir. Pranav Amin: Thank you, Isha. Good evening, everyone, and thank you for joining us to discuss Alembic Pharmaceuticals performance for Q1 FY27. I will give you a brief perspective of the quarter and the performance across our businesses, key strategic developments and our outlook for the balance of the year. Then Krishnan, our CFO, will take you through the financial performance in greater detail. Q1 FY27 has been a strong start to the year with broad-based growth across all the businesses and continued execution on the strategic priorities that we outlined at the beginning of the year. The external environment continues to remain competitive with pricing pressure, regulatory expectations and geopolitical uncertainties. But the quarter reinforces our belief that execution quality, portfolio choices, manufacturing capabilities and launch discipline are increasingly becoming the key differentiators. During the quarter, consolidated revenue grew by 26% year- on-year supported by growth across all our major businesses. India branded business grew 7%. International Generics grew 37% and the API business grew 33%. Starting with the India Branded business, growth was supported by continued strengthening of focus brands, Specialty Therapies and the Animal Health division. Animal Health delivered a particularly strong quarter with 24% growth, while key therapies such as Gynecology, Gastrology and Ophthalmology continued to perform well. We are also seeing encouraging trends in field productivity and operating metrics. Our strategic priorities for India business is anchored on building a robust chronic portfolio, generating high-quality prescriptions, deepening engagement with specialty physicians and driving sharper, more disciplined commercial execution across the field force. With the appointment of Mr. Ramesh Juneja as Sales and Marketing Head for Human Health business, we have strengthened the execution leadership. Page 2 of 15 Alembic Pharmaceuticals Limited August 04, 2026 These initiatives are likely to position the India Branded business to accelerate towards market level growth over the coming quarters. Moving on to the international business. The standout feature for the quarter was the continued strength of the U.S. Generics business. U.S. revenues grew 49% year-on-year, supported by volume growth, new launches, especially Bosutinib and improving utilization of our manufacturing assets. Pricing pressure remains in the environment, but growth during the quarter was predominantly volume driven. During the quarter, we launched 7 products, filed 4 ANDA's and received 10 approvals, further strengthening the launch platform for future growth. So let me talk about the Branded Specialty business. The first 3 months were more of a soft launch, and we are encouraged -- this is the branded specialty business in the U.S. I'm talking about. The first 3 months were a soft launch, and we are encouraged by the good reception to both the product and its messaging. In parallel, we are adding new products to strengthen our women's health franchise. As the U.S. Branded Specialty business scales up over the next few quarters, we will see a positive contribution to profit, which should consequently drive a broader enhancement in consolidated margins. Coming to the ex-U.S. markets, they performed very well, supported by growth across markets. The API business also delivered a strong volume-led growth despite ongoing pressure in the market. Beyond the quarterly performance, we continued investing behind the long-term growth drivers of the company. We advanced our pipeline through additional filings and approvals, progressed our peptide development program, expanded partnership-led opportunities and continued building the US branded business platform. We also continued investments in manufacturing capabilities, debottlenecking initiatives and capacity enhancement programs that will support future growth and improve operating leverage. Turning to the outlook. The first quarter has provided us with greater visibility into the trajectory of the business, particularly the US Generics segment. At the beginning of the year, we had indicated that the US Generics could grow in the low to mid-teens based on the performance and the trends we're seeing in Q1, the launch outlook and current volume trends, we now expect the US business to grow mid to high teens in the year, subject to normal market conditions and continued execution. Growth guidance for the other businesses remains as indicated earlier. As a result, we believe the overall growth outlook for the company can improve from the low double-digit range that we had discussed earlier to closer to the mid-teen range for FY27. Importantly, this improved outlook is not being driven by any change in our investment agenda. We will continue investing behind R&D, the US branded platform, manufacturing capabilities and future growth opportunities while maintaining discipline on capital allocation and profitability. Overall, the quarter reinforces our confidence in the business, the quality of our growth platform and our ability to deliver strong growth while continuing to invest for the future. With that, let me hand over to our CFO, Krishnan. G. Krishnan: Thank you, Pranav. Good evening, everyone. And before I begin, I would like to mention that during this call, we may make certain forward-looking statements, and these statements are Page 3 of 15 Alembic Pharmaceuticals Limited [Showing first 8,000 characters — download PDF for full document]